Skip to main content

Table 2 Mutations found in the hotspot gyrA of S. Typhi

From: Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta

Mutation

Susceptibility Profile

Study

Asp82Asn

NAL (R)

[18]

Ser83Phe

OFX (R), CIP (R), NAL (R)

[16] f

CIP (DS)

[17]

CIP (R), NAL (R)

[18]

NAL (I) CIP (S)

[18]

CIP (R), NAL (R)

[18] a,e

NAL (I) CIP (S)

[18] b

NAL (R), CIP (S)

[19]n

NAL (R), CIP (I)

[19]n,o,p

CIP (R), NAL (R)

[26]

OFX (R), CIP (R), NAL (R)

[27] g

CIP (DS), NAL (R)

[28]

CIP (R), NAL (R)

[28] j

CIP (DS), NAL (R)

[29] k

CIP (R), NAL (R)

[29]m

Ser83Tyr

CIP (DS)

[17]

NAL (I), CIP (S)

[18] c

NAL (R), CIP (I)

[19]

NAL (R), CIP (S)

[19]

CIP (R), NAL (R)

[19]q

OFX (R), CIP (R), NAL (R)

[27] h

CIP (DS), NAL (R)

[28]

CIP (DS), NAL (R)

[29] k

CIP (R), NAL (R)

[29] l

Asp87Asn

CIP (R), NAL (R)

[19]

NAL (R), CIP (I)

[19] r

NAL (R), CIP (S)

[19] r,s

CIP (R), NAL (R)

[19] s

CIP (R), NAL (R)

[18] d,e

NAL (I) CIP (S)

[18] b

CIP (R), NAL (R)

[26]

OFX (R), CIP (R), NAL (R)

[27] i

CIP (R), NAL (R)

[28] j

CIP (DS), NAL (R)

[29] k

Asp87Val

OFX (R), CIP (R), NAL (R)

[16] f

Asp87Gly

CIP (DS)

[17]

NAL (R), CIP (I)

[19] t

CIP (R), NAL (R)

[19] t

CIP (R), NAL (R)

[29] m

Ala119Glu

CIP (DS)

[17]

Glu133Gly

NAL (R), CIP (S)

[19] n,r,u

NAL (R), CIP (I)

[19]n,o,p,r,t

CIP (R), NAL (R)

[19] q,t

Gly133Glu

NAL (DS)

[30]v

  1. aDouble mutations: gyrA Ser83Phe and gyrB Gly435Ala; gyrA Ser83Phe and gyrB Gly435Glu; gyrA Ser83Phe and gyrB Gly435Val
  2. bFour mutations in one isolate: gyrA Ser83Phe, gyrA Asp87Asn, gyrB Gly435Glu, and parC Ser80Ile
  3. cDouble mutations in one isolate: gyrA Ser83Tyr and parE Ser493Phe
  4. dDouble mutations in one isolate: gyrA Asp87Asn and gyrB Gly435Glu
  5. eThree mutations in one isolate: gyrA Ser83Phe, gyrA Asp87Asn, and parC Ser80Ile
  6. fThree mutations: gyrA Ser83Phe, gyrA Asp87Val, and parC Ser80Ile
  7. gThree mutations: gyrA Ser83Phe, gyrA Asp87Val, and parC Ser80Ile; Double mutations: gyrA Ser83Phe and parC Glu84Gly; gyrA Ser83Phe and parE Ala364Val, in some isolates
  8. hDouble mutations: gyrA Ser83Tyr and parE Ala364Val
  9. iDouble mutations: gyrA Asp87Asn and parE Ala364Val
  10. jDouble mutations: gyrA Ser83Phe and gyrA Asp87Asn
  11. kSingle mutation with increased efflux pump activity for nalidixic acid
  12. lSingle mutation with the presence of qnrS and increased efflux pump activity for both nalidixic acid and ciprofloxacin
  13. mThree mutations: gyrA Ser83Phe, gyrA Asp87Gly, parC Glu92Lys, and increased efflux pump activity for nalidixic acid
  14. nDouble mutations: gyrA Ser83Phe and gyrA Glu133Gly
  15. oThree mutations: gyrA Ser83Phe, gyrA Glu133Gly, and parE Ile444Ser
  16. pFour mutations: gyrA Ser83Phe, gyrA Glu133Gly, parE Ile444Ser, and parE Tyr434Ser
  17. qFour mutations: gyrA Ser83Tyr, gyrA Asp87Asn, gyrA Glu133Gly, and parC Glu84Lys
  18. rDouble mutations: gyrA Asp87Asn and gyrA Glu133Gly
  19. sSingle mutations gyrA Asp87Asn and the presence of aac(6′)-ib-cr4
  20. tDouble mutations: gyrA Asp87Gly and gyrA Glu133Gly
  21. uDouble mutations: gyrA Glu133Gly and gyrB Ser426Gly
  22. vDouble mutations: gyrA Ser83Phe and gyrA Gly133Glu